The ACCC’s Compliance and Enforcement Priorities for 2025 to 2026 recognise that cost of living, the cost of doing business and the ongoing impacts of the digital economy’s transformation and disruption are some of the most pressing challenges and opportunities facing Australia’s economy and community. In this update we explain the key areas which will be the subject of the ACCC’s scrutiny and focus in 2025/26.
Read more
On 29 November, 2024 amendments to the Australian privacy law made by the Privacy and Other Legislation Amendment Bill 2024 (the ‘Bill’) passed and came into effect on 11 December 2024 (the day after receiving Royal Assent). In this Update we provide an overview of some of the key changes arising from the Bill, together with guidance on steps that businesses can consider taking now to prepare for the changes and privacy law compliance generally.
Read more
With consumers increasingly relying on on-line reviews about products or services in making purchase decisions, “one star”, “negative” or “fake” reviews can result in serious harm, reputational damage and loss of business. A recent court decision shows how posting a “one star” Google review can be a very costly exercise for reviewers, particularly where the review is defamatory and false or fake. Businesses and individuals subjected to “one star” reviews, can take legal action.
Read more
Advertising prescription-only medicines to the public can result in criminal and civil penalties for both corporations and individuals amounting to many millions of dollars. The Therapeutic Goods Administration has been stepping up its enforcement actions to stop unlawful advertising to the public of therapeutic goods including prescription-only medicines. This article includes some strategies that businesses can implement to minimize the risk of non-compliance.
Read more
Recent cases show that failure by businesses to ensure that environmental sustainability marketing claims are accurate can result in legal action being taken by regulators for false representations and misleading and deceptive conduct exposing the company and its directors to significant penalties and compensation claims.
Read more